NCT06440850 2026-02-02
Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E Mutation
City of Hope Medical Center
Phase 2 Recruiting
Clinical Trials
9 trialsNCT05668962 2024-12-12
Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC
Massachusetts General Hospital
Phase 2 Recruiting
NCT06405217 2024-05-08
Recombinant Human Thyroid Stimulating Hormone for Radioiodine 131I Treatment
Nanjing First Hospital, Nanjing Medical University
Phase NA Recruiting
NCT04137185 2024-03-06
Clinical Trial of Dose-tolerance, Pharmacokinetics and Iodine Uptake For rhTSH In Post-thyroidectomized Patients
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 1/2 Completed
NCT04447183 2023-10-23
DTC
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 2 Unknown
NCT04964284 2023-10-23
Efficacy and Safety Study of rhTSH for Adjuvant Radioiodine Ablation Therapy in Patients With Differentiated Thyroid Cancer
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 3 Unknown
NCT01837745 2023-05-17
ESTIMABL2
Gustave Roussy, Cancer Campus, Grand Paris
Phase 3 Active not recruiting
NCT03244956 2021-09-28
MERAIODE
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2 Unknown
NCT00295763 2015-03-18
A New Study to Follow-up Thyroid Cancer Patients Who Participated in a Previous Study, Which Compared the Success of Destruction of the Thyroid Remnant Using Standard Treatment or Thyrogen.
Sanofi
Phase 3 Completed